Alumis Inc. (United States)

Homepage: alumis.com

Alternate names: Alumis, Alumis Inc.

ROR: 017z2jz89

OpenAlex ID: I4405267105

Improving Collection and Analysis of Overall Survival Data

2024 · Lisa R. Rodriguez, Nicole J. Gormley, et al. · Clinical Cancer Research · 23

PDF

Using Radiomics in Cancer Management

2024 · Shivaani Kummar, Ruixiao Lu · JCO Precision Oncology · 22

Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice

2024 · Christopher W. Smith, Joana Campos, et al. · Blood Advances · 20

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design

2024 · Sibel Ucpinar, Joyce K. Kwan, et al. · Clinical and Translational Science · 13

PDF

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study

2025 · Andrew Blauvelt, Petr Arenberger, et al. · Journal of the American Academy of Dermatology · 12

Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study

2025 · Kim A. Papp, Shahram Jacobs, et al. · Journal of the American Academy of Dermatology · 10

PDF

64301 Patient-Reported Outcomes in the Phase 2 Studies of ESK-001, an Oral Allosteric TYK2 Inhibitor, in Adults with Moderate-to-Severe Plaque Psoriasis

2025 · Andrew Blauvelt, Steven Kempers, et al. · Journal of the American Academy of Dermatology · 2

Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review

2026 · April W. Armstrong, James G. Krueger, et al. · Dermatology and Therapy · 1

PDF

The genetic architecture of gene expression in individuals of African and European ancestry

2024 · Kipper Fletez-Brant, Renan Sauteraud, et al. · medRxiv · 1

PDF

53968 Pharmacokinetic and Pharmacodynamic Characteristics of ESK-001, an Oral Allosteric TYK2 Inhibitor, in Phase 1 Healthy Volunteer Trials

2024 · SIbel Ucpinar, Claire Langrish · Journal of the American Academy of Dermatology · 1

PDF

Envudeucitinib Provides Rapid and Sustained Itch Relief, Including Complete Itch Resolution, in Patients with Moderate-to-Severe Plaque Psoriasis: 24 Week Results from the Phase 3 ONWARD 1 and ONWARD2 Trials

2026 · Jason E Hawkes, Mark Lebwohl, et al. · SKIN The Journal of Cutaneous Medicine

PDF

Sustained and Increasing Skin Clearance with Continuous Envudeucitinib in Moderate-to-Severe Plaque Psoriasis: Results from the ONWARD3 Long-Term Extension Study

2026 · Mark G. Lebwohl, Andrew Blauvelt, et al. · SKIN The Journal of Cutaneous Medicine

PDF

Achievement of Clinically Meaningful Treat-to-Target Thresholds with Envudeucitinib in Moderate-to-Severe Plaque Psoriasis: Results from ONWARD1 and ONWARD2

2026 · Benjamin D. Ehst, Joe K. Tung, et al. · SKIN The Journal of Cutaneous Medicine

PDF

Lonigutamab inhibits hyaluronan production by reducing IGF-1R levels in thyroid eye disease orbital fibroblasts

2026 · Elisa Roztocil, Farha Husain, et al. · The Journal of Clinical Endocrinology & Metabolism

0111 Envudeucitinib, an allosteric TYK2 inhibitor, inhibits TYK2-relevant biomarkers in skin using spatial transcriptomics

2026 · N. Narayan, J. Hoffman, et al. · Journal of Investigative Dermatology

73714 Envudeucitinib Attenuates Inflammatory Biomarkers in Plaque Psoriasis at Both a Proteomic and Transcriptomic Level: A Subgroup Analysis of Tape Strip Biomarkers from the STRIDE Phase 2 Clinical Trial

2026 · Mera Tilley, Joshua Hoffman, et al. · Journal of the American Academy of Dermatology

SBR Special Section “Overall Survival in Oncology Trials and Drug Development”

2026 · Ruixiao Lu, Lisa R. Rodriguez, et al. · Statistics in Biopharmaceutical Research

257 Transcriptomic and Proteomic Modulation in Psoriatic Skin Following Envudeucitinib Treatment: Subgroup Analysis of a Phase 2 Randomized Trial

2025 · Jerry Zhou, Jacob Fiedler, et al. · Journal of Investigative Dermatology

62945 Pharmacokinetics, Safety, and Tolerability of ESK-001, an Allosteric TYK2 Inhibitor for Plaque Psoriasis: Evaluation in Asian Populations Compared to Caucasians

2025 · Sibel Ucpinar, Yook Noh, et al. · Journal of the American Academy of Dermatology

0476 Maximal and sustained TYK2 inhibition: The key to higher efficacy with oral allosteric inhibitors

2025 · S. Ucpinar, J.K. Kwan, et al. · Journal of Investigative Dermatology

PDF

0116 ESK-001, an allosteric TYK2 inhibitor, inhibits TYK2-and psoriasis-relevant biomarkers in skin using spatial transcriptomics

2025 · N. Narayan, J.D. Hoffman, et al. · Journal of Investigative Dermatology

PDF

COL1A1 proximal promoter topology regulates its transcriptional response to transforming growth factor β

2024 · Elena Hitraya, Svetlana Gaidarova, et al. · Connective Tissue Research

PDF

Works count: 22

Citation count: 441